<DOC>
	<DOCNO>NCT00440375</DOCNO>
	<brief_summary>The purpose study evaluate effect rosiglitazone bone metabolism ass association change bone turnover parameter plasma cytokine level postmenopausal diabetic woman</brief_summary>
	<brief_title>Effects Rosiglitazone Bone Postmenopausal Diabetic Women</brief_title>
	<detailed_description>Fifty-six obese , drug naive patient type 2 diabetes mellitus enrol complete study . Twenty-six healthy subject match age body mass index ( BMI ) serve nondiabetic control . All subject postmenopausal woman last menses least 2 year . After baseline measurement , subject instruct follow weight-maintaining diet , base ADA recommendation , also encourage walk jog least 30 min daily . Subsequently , 28 diabetic subject randomly assign receive rosiglitazone ( 4 mg/day ) . Twenty-eight diabetic subject diet alone . The randomization procedure base random sequence . All subject complete clinical examination , anthropometric measurement , laboratory test baseline end 12th week study . Laboratory investigation include assessment : ( ) glycemic control ( HbA1c , fast plasma glucose insulin level , homeostasis model assessment ( HOMA ) index ( 22 ) ; ( ii ) serum bsALP active human osteocalcin concentration ( OCL ) markers bone formation ; ( iii ) urine deoxypyridinoline ( DPD ) marker bone resorption . Other non-specific bone marker include serum total ALP activity , urinary calcium ( Ca ) phosphate ( PO4 ) concentration also measure . Urine concentration DPD ( nmol/L ) , Ca PO4 ( mmol/L ) correct respective urine creatinine ( Cr ) concentration mmol/L ( Urine DPD/Cr , Urine Ca/Cr Urine PO4/Cr respectively ) . In addition , fast blood sample analyze plasma cytokine level include IL-1β , IL-6 TNF-α , haptoglobin level .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Newly diagnose type 2 diabetes mellitus Postmenopausal period Recent fracture osteoporosis Drugs may affect calcium bone metabolism drug know interfere cytokine release Thyroid , parathyroid , pituitary , nutritional , inflammatory , hepatic , renal , neoplastic disorder Severe cardiovascular disease</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
</DOC>